NEUROG3's role in forming pancreatic progenitor cells
Official title: NGN3 as a mediator of human pancreatic progenitor cell competence
Funded at Children's Hospital of Los Angeles · NIH-11607801 · Data updated 2026-11-12
Researchers are studying how a NEUROG3 gene flaw in patient-derived stem cells affects the development of pancreas cells that can later become insulin-producing cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hospital of Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $435,907 |
| NIH project number | 1R56DK145077-01A1 |
| Project ID | NIH-11607801 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with NEUROG3-related mutations or their derived iPSC lines whose cells are used to model pancreatic development.
✕Less likely to help
Healthy individuals without NEUROG3 mutations may not directly benefit from this study.
What this research studies
This project uses patient-specific stem cells with NEUROG3 mutations to explore how pancreatic progenitor cells gain their competence. By editing and testing different stem cell lines, the team aims to uncover when NEUROG3 acts to set up proper development. The work could lead to better methods for turning stem cells into functional, insulin-secreting cells, which are needed for disease modeling and potential therapies. Results may inform drug screening and strategies for diabetes cell replacement. The study plans to generate new datasets and tools to make findings more generalizable to the broader population.
Why it matters
Potential benefit: If successful, it could improve how stem cells are turned into insulin-secreting beta-like cells and advance diabetes research and potential therapies.
How similar studies have gone: Prior work suggests NEUROG3 is important for pancreatic development, but this study seeks to define a new role during a critical development window using patient-derived cells.
Where this research is happening
-
Children's Hospital of Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Georgia, Senta K — Children's Hospital of Los Angeles
- Study coordinator: Georgia, Senta K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.